Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | GRPR | P30550 | 1/20 | 0.37 |
| ▸ | CALCR | P30988 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16507942 | 0.98 | ACE (0.39) | ACECRHR1CRHR2GRPRCALCR | |
| SCHEMBL16359347 | 0.91 | ACE (0.46) | ACE | |
| SCHEMBL16358941 | 0.91 | ACE (0.46) | ACE | |
| SCHEMBL16507899 | 0.89 | PTPN1 (0.44) | ACE | |
| SCHEMBL16507850 | 0.84 | NPY4R (0.47) | ACECRHR1CRHR2 | |
| SCHEMBL31020877 | 0.80 | ACE (0.47) | ACE | |
| SCHEMBL16507827 | 0.80 | ACE (0.49) | ACE | |
| SCHEMBL13363654 | 0.79 | ACE (0.49) | ACE | |
| SCHEMBL16508075 | 0.78 | NPY4R (0.53) | — | |
| SCHEMBL29790444 | 0.76 | NPY4R (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | ANTHOR THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
| WO-2010053548-A2 | PTHR1 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | PTH1R, MC1R, CASR | ACE 3206/4885CRHR1 210/4885CRHR2 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.